CYT News and Press, Cyteir Therapeutics Inc.

2023-03-23 16:44:01 ET Cyteir Therapeutics press release ( NASDAQ: CYT ): Q4 GAAP EPS of -$0.25. Cash and cash equivalents as of December 31, 2022 were $147.1 million, which are expected to fund planned operations into 2026. For further details see: Cyteir Therap...

Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...

Oncology company Cyteir Therapeutics ( NASDAQ: CYT ) promoted Vice President of Finance David Gaiero to the post of a CFO. Gaiero will continue to manage the finance department and oversee the overall financial operations, reporting directly to CEO Markus Renschler. Source: ...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...

BofA Securities has downgraded Cyteir Therapeutics ( NASDAQ: CYT ) to neutral from buy citing the company's recent decision on a pipeline prioritization to focus on combination therapies using its candidate CYT-0851 for ovarian cancer. The firm halved its price target to $2 (~17%...

Cyteir Therapeutics ( NASDAQ: CYT ) on Thursday said it would prioritize clinical development of its potential ovarian cancer therapy CYT-0851 and would reduce its workforce as part of the prioritization. The company said that CYT-0851 had shown encouraging preliminary clinical activi...

- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...

Cyteir Therapeutics press release ( NASDAQ: CYT ): Q3 GAAP EPS of -$0.31 beats by $0.08 . Cash and cash equivalents as of September 30, 2022 were $153.9 million. Cash and cash equivalents are expected to fund planned operations into the second half of 2024. R...

- Initial data from CYT-0851 monotherapy solid tumor Phase 2 cohorts are now expected in first quarter of 2023 - Initial data from Phase 1 combination solid tumor cohorts are expected in first half of 2023 - Ended quarter with approximately $153.9 million in cash Cyteir ...

- Poster details the research into CYT-0851 mechanism of action and identification as an inhibitor of monocarboxylate transporter activity Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synt...